Exploration of Medicine

From: The diagnostic conundrum in non-alcoholic fatty liver disease

Table 3

Summary of imaging techniques for evaluation of liver stiffness in patients with NAFLD

NMR-based techniques
	End-point	AUROC	Cutoff (kPa)	Diagnostic accuracy (%)	Study population, reference
2D MRE
	AF	0.93–0.96	3.6–4.8	Se 85-Sp 85; PPV 71-NPV 93	628 NAFLD, [77, 113]
	Cirrhosis	0.9	> 4.1	Se 86-Sp 93; PPV 53-NPV 98	384 NAFLD, [77]
3D MRE
– 40Hz	AF	0.98	2.43	Se 100-Sp 94; PPV 72-NPV 100	100 NAFLD, [114]
– 60Hz	AF	0.92	3.4	Se 100-Sp 94; PPV 72-NPV 100
– 40Hz	Cirrhosis	0.99	3.2	Se 86-Sp 96; PPV 81-NPV 97
– 60Hz	Cirrhosis	0.98	4	Se 86-Sp 96; PPV 81-NPV 97

Return to article view

US-based techniques
	End-point	AUROC	Cutoff (kPa)	Diagnostic accuracy (%)	Study population, reference
TE (Fibroscan®)
- M Probe	AF	0.87	7.6–8	Se 89-Sp 77; PPV 43-NPV 95	1, 540 NAFLD, [77]
- XL Probe	AF	0.86	5.7–9.3	Se 75-Sp 74; PPV 43-NPV 95	579 NAFLD, [77]
- M Probe	Cirrhosis	0.92	10.3–11.3	Se 87-Sp 86; PPV 46-NPV 98	1, 362 NAFLD, [77]
- XL Probe	Cirrhosis	0.94	7.2–16	Se 84-Sp 80; PPV 39-NPV 98	654 NAFLD, [77]
ARFI
	SF	0.89		Se 80-Sp 85	723 NAFLD, [136]
2D-SWE
	SF	0.85	9.2		156 NAFLD, [138]
	AF	0.89	> 8.3 < 10.7	Se 71-Sp 90	291 NAFLD, [139]
	Cirrhosis	0.91	13.5		156 NAFLD, [138]
	Cirrhosis	0.88	> 10.5	Se 90-Sp 72	291 NAFLD, [139]

AF (F3); Cirrhosis (F4); significant fibrosis: 4 > F ≥ 2